Condition: Chronic Graft-versus-host-disease · Sponsor: Syndax Pharmaceuticals
This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.
This description comes directly from the study's public registry record.
Syndax Pharmaceuticals · 781-419-1400 · clinicaltrials@syndax.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham - Children's of Alabama | Birmingham, Alabama, United States | Completed |
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| City of Hope | Duarte, California, United States | Active Not Recruiting |
| University of Southern California Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| University of California, Los Angeles (UCLA) - Medical Center | Los Angeles, California, United States | Completed |
| Stanford Cancer Center | Stanford, California, United States | Active Not Recruiting |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | Active Not Recruiting |
| University of Florida (UF) | Gainesville, Florida, United States | Completed |
| Mayo Clinic - Jacksonville | Jacksonville, Florida, United States | Active Not Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| AdventHealth Orlando | Orlando, Florida, United States | Completed |
| Moffitt | Tampa, Florida, United States | Active Not Recruiting |
+ 109 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04710576